elotuzumab,rilzabrutinib,obexelimab
zenas,sanofi,bms
['elotuzumab', 'obexelimab', 'rilzabrutinib']
new igg4-rd therapeutic avenues,
mechanistically driven (b cell-ctl interaction): inebilizumab: registered for nmo, ph3 now
obexelimab: novel dual moa ?safer, ph3 now
rilzabrutinib: btki, ph2 now
elotuzumab: targets slamf7, mm registered, nih study john stone #acr22 
Rheumatologist and clinical pharmacologist, world traveller pretences on the upswing, sometimes podcast host for @austprescriber and others. All opinions my own